Roche: EU Approves Tecentriq For People With Specific Type Of Lung Cancer
SOUTH SAN FRANCISCO (dpa-AFX) - Swiss drug major Roche (RHHBY) announced Wednesday that the European Commission has approved Tecentriq (atezolizumab) for people with specific type of lung cancer.
Tecentriq has been approved as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer or NSCLC whose tumours have high PD-L1 expression, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
Roche noted that Tecentriq is now the first and only single-agent cancer immunotherapy with three dosing options, allowing administration every two, three or four weeks. This gives physicians and patients greater flexibility on how they manage their treatment.
Cranfield University: Developing future leaders in technology and management ANI | Updated: May 05, 2021 18:10 IST
New Delhi [India], May 5 (ANI/SRV Media): Today, educational institutes like Cranfield University, UK, have various MSc and Management courses to benefit every aspiring student.
The university has more than 100 courses, full-time and part-time, which cover a broad range of subjects where graduates can go on to help solve the big issues facing society, from decarbonizing transport systems to delivering more sustainable industrial processes.
Cranfield University, set in the heart of the UK s Cambridge, Milton Keynes, Oxford arc, focuses on attracting students and faculty worldwide to learn in the best environment. Cranfield offers courses around diverse fields including Aerospace, Defence and Security, Environment and Agrifood, Energy and Power, Manufacturing, Transport Systems and Water, alongside Leadership and Management.
Viewpoint Molecular Targeting(TM) Appoints Frank Morich, M D , Ph D to its Board of Directors tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
28.04.2021 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 7 to 2 in favor of maintaining accelerated approval of Tecentriq . Seite 1
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favor of maintaining accelerated approval of Tecentriq
® (atezolizumab) for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC, bladder cancer) who are not eligible for cisplatin-containing chemotherapy and whose tumors express high levels of PD-L1 (PD-L1–stained tumor-infiltrating immune cells covering ≥5 percent of the tumor area) as determined by an FDA-approved test or are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. Today’s ODAC meeting is part of an industry-wide review of accelerated approvals with confirmatory trials that have not met their primary endpoint(s) and have yet to gain regular approvals. The advisory committee provides the FDA with independent opinions and recommendations from outside medical expe